Propanc Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| PRP Engineering Run | 31 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Phase 1b First-In-Human Clinical Trial Enrollment Quarterly0.0Target: 30-40 patients
Quarterly Net Loss Quarterly-6.4MTarget: Reduction in cash burn
Cash Balance Quarterly443.7KTarget: Sufficient runway to support Phase 1b trial
Watch Items
- GMP Manufacturing of PRP Lead AssetTrigger: Preproduction in August 2026, Engineering run in October 2026, GMP manufacture in December 2026Action: Monitor CDMO progress to ensure clinical supply is ready for the planned Australian trial application.
- Nasdaq Minimum Bid Price ComplianceTrigger: Maintaining a closing bid price of at least $1.00 per share for 10 consecutive business daysAction: Evaluate the impact of the 1-for-25 reverse stock split implemented on May 18, 2026, and monitor potential delisting risks.
- Series C Private Placement Facility DrawdownsTrigger: Accessing the remaining portion of the up to $100 million financing facilityAction: Track subsequent tranches (such as the $0.5 million tranche received post-Q3) to ensure adequate R&D funding.
Research as of 20 Jun 2026